BT-600
Ulcerative Colitis
Phase 1Active
Key Facts
About Biora Therapeutics
Biora Therapeutics is a clinical-stage biotech innovating oral drug delivery systems designed to replace injectable biologics. The company is advancing two primary platforms: the BioJet™ platform for systemic, needle-free delivery of large molecules like GLP-1 agonists, and the NaviCap™ platform for targeted delivery of therapeutics to specific GI tract sites. While demonstrating promising preclinical and early clinical data, the company has recently undergone significant financial restructuring, including a Chapter 11 sale process completed in early 2025, to position itself for future growth. Its technology aims to address major compliance and accessibility challenges in treating chronic conditions.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| BB265 | BiomeBank | Phase 1 |
| PALI-2108 | Palisade Bio | Phase 2 |
| ALTB-268 | AltruBio | Phase IIa |
| AIM-HI-UC | PathAI | Clinical Trials |
| Patient Stratification in Ulcerative Colitis | Enable Medicine | Research |
| Mesalazine (Lifecycle Management) | Dr. Falk Pharma | Approved/Phase 3 |
| AhR Agonist Program | Azora Therapeutics | Phase 1b |
| R-3750 | Virtici | Phase 1 |
| GPR35 Inhibitor | ThirtyFiveBio | Preclinical |
| Asacol® (mesalazine) | Tillotts Pharma | Approved |
| MB310 | Microbiotica | Phase 1b |
| '1805 | Revolo Biotherapeutics | Phase 2 (Planned) |